Earnings call transcript: Medpace Holdings Q1 2026 sees earnings beat but stock tumbles

Medpace beat Q1 2026 expectations with EPS of $4.28 versus $3.92 consensus and revenue of $706.6 million versus $697.6 million, but shares fell 23.7% premarket to $380 after the company flagged elevated cancellations and a weak 0.88 net book-to-bill. Management said cancellations were driven by project-specific issues, while guidance was reaffirmed and FY2026 revenue outlook remained intact at $2.81 billion. The call highlighted concern around future growth durability, especially as backlog coverage beyond one year continues to decline.

Analysis

The key signal is not the quarter itself; it’s the company publicly admitting the model is now constrained by cancellations rather than demand. That changes MEDP from a clean compounder to a more cycle-sensitive backlog conversion story: the near-term earnings power is intact, but the forward multiple should compress because the market will discount a lower probability that today’s pipeline turns into revenue at the same rate over the next 2-4 quarters.

Second-order, this is less about biotech funding collapsing and more about sponsor behavior becoming more opportunistic. In a market where biotech M&A is lifting asset prices but also shortening decision windows, CROs tied to earlier-stage programs can see more starts, more stop/starts, and more contract volatility. MEDP’s refusal to chase large pharma helps margin quality, but it also leaves the company structurally exposed to the highest-cancellation parts of biotech, so any moderation in GLP-1/metabolic enthusiasm or oncology funding would hit the forward book harder than the current guide implies.

The selloff looks directionally right, but likely overstates immediate revenue risk relative to 2027 risk. This is a stock where the next two quarters may still look fine because revenue is supported by prior starts and high pass-through, but the multiple is now exposed to a tougher setup if net bookings stay sub-1.0 and pre-backlog continues to leak. The real catalyst is not one print; it’s whether management can show 2 consecutive quarters of rising gross awards and a book-to-bill back toward 1.0 without relying on lower cancellations.

Consensus is too focused on the headline EPS beat and too little on the admissions embedded in the Q&A: the company is telling you sequential growth is now in question. That makes the stock vulnerable to further derating even if estimates hold, because investors tend to pay for visibility in CROs, not just current execution. The contrarian angle is that if cancellations normalize faster than expected, the magnitude of the drawdown creates a tradable squeeze — but until then, the path of least resistance is lower.

Key Decisions for Investors

• Short MEDP common into any post-earnings bounce over the next 1-3 weeks; thesis is multiple compression from 25x toward high-teens on deteriorating forward visibility. Risk: a quick revert in booking sentiment or a stabilization of cancellations.
• Buy MEDP put spreads 2-4 months out, targeting a second leg lower if the next quarter still shows sub-1.0 book-to-bill. Best structure: downside defined, because the stock can re-rate violently on any sign of booking stabilization.
• Pair trade: short MEDP / long a higher-visibility large-cap CRO or healthcare services name over the next quarter. The trade monetizes the market’s willingness to pay for predictability versus raw growth with weakening conversion.
• If already long MEDP, reduce size on strength and wait for proof of two consecutive quarters of improving gross awards before re-adding. The risk/reward is poor until the market sees cancellation normalization, not just management commentary.
• Watch for a tactical long entry only if shares retest and hold a post-gap level while management confirms book-to-bill improvement; otherwise avoid catching the falling knife given 2027 visibility risk.